Search research articles
Contact Us
Filters
Showing results (601-610 of 704) with videos related to
Page
of 71
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2021
Hematological immune related adverse events after treatment with immune checkpoint inhibitors
Rafaela Kramer, Anne Zaremba, Alvaro Moreira, et al.
The British Journal of Dermatology
|
March 16, 2022
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study
Xue Bai, Alexander N Shoushtari, Allison Betof Warner, et al.
The New England Journal of Medicine
|
September 29, 2019
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Lancet (London, England)
|
April 3, 2022
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Jason J Luke, Piotr Rutkowski, Paola Queirolo, et al.
Nature Medicine
|
February 9, 2021
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
Alexander M Menzies, Rodabe N Amaria, Elisa A Rozeman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2023
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
J M Versluis, A M Menzies, K Sikorska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2013
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma
Kerstin Trunzer, Anna C Pavlick, Lynn Schuchter, et al.
JAMA Oncology
|
September 23, 2018
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
Daniel Y Wang, Joe-Elie Salem, Justine V Cohen, et al.
The New England Journal of Medicine
|
April 17, 2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 21, 2016
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo, Xuan Wang, Kaitlin M Woo, et al.
Page
of 71
Search research articles
Search
Showing results (601-610 of 704) with videos related to
Sort By:
Page
of 71
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2021
Hematological immune related adverse events after treatment with immune checkpoint inhibitors
Rafaela Kramer, Anne Zaremba, Alvaro Moreira, et al.
The British Journal of Dermatology
|
March 16, 2022
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study
Xue Bai, Alexander N Shoushtari, Allison Betof Warner, et al.
The New England Journal of Medicine
|
September 29, 2019
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Lancet (London, England)
|
April 3, 2022
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Jason J Luke, Piotr Rutkowski, Paola Queirolo, et al.
Nature Medicine
|
February 9, 2021
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
Alexander M Menzies, Rodabe N Amaria, Elisa A Rozeman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2023
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
J M Versluis, A M Menzies, K Sikorska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2013
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma
Kerstin Trunzer, Anna C Pavlick, Lynn Schuchter, et al.
JAMA Oncology
|
September 23, 2018
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
Daniel Y Wang, Joe-Elie Salem, Justine V Cohen, et al.
The New England Journal of Medicine
|
April 17, 2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 21, 2016
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo, Xuan Wang, Kaitlin M Woo, et al.
Page
of 71